EarningsQ2 2026 Earnings Report
MX:MRVI Q2 2026 EPS Results
Actual EPS-$0.36
Consensus EPS-$0.80
Beat/MissBeat by +$0.44
One Year Ago EPS-$1.45
MX:MRVI Q2 2026 Revenue Results
Actual Revenue$935.12M
Expected Revenue$884.79M
Beat/MissBeat by +$50.34M
YoY Revenue Growth+8.53%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:MRVI Upcoming Earnings
Maravai Lifesciences Holdings's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:MRVI Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed strong operational progress and financial improvement: revenue growth, large margin expansion, significantly improved adjusted EBITDA, record customer additions, product launches and patent wins, plus a materially strengthened balance sheet via refinancing. The primary negatives are that GAAP losses persist, certain businesses (CDMO and some new products) remain lumpy or early-stage, and timing risk exists around large program-driven orders and GMP conversions. On balance, the call emphasized accelerating commercial execution and durable margin improvement, with management maintaining prudent revenue guidance while raising confidence in profitability.Company Guidance
Quarterly Revenue Growth
Total revenue of $51.4 million in Q2 2026, representing 9% year-over-year growth versus prior-year period.
TriLink Revenue and Mix Strength
TriLink revenue increased 12% year-over-year and represented 67% of total revenue; this segment contributed $7.0 million of adjusted EBITDA (improving >$14.2 million YoY) driven by higher-margin GMP product mix and discovery mRNA demand.
GMP Consumables Surge
GMP consumables grew 55% year-over-year in Q2, driven by large CleanCap clinical orders and the first GMP enzyme order, highlighting material demand for clinical-grade supplies.
Discovery mRNA Momentum
Discovery mRNA grew 17% year-over-year; the company added a record 67 new discovery customers in Q2 and reported strong uptake of ModTail with >125 customers using the technology one year post-launch.
Adjusted Gross Margin Expansion
Adjusted gross margin expanded by more than 1,600 basis points year-over-year to 58.9%, reflecting favorable product mix and operating improvements.
Adjusted EBITDA Improvement and Guidance Raise
Adjusted EBITDA improved by $19.1 million year-over-year to $8.7 million for Q2. Full-year adjusted EBITDA guidance was raised to $33–$35 million, representing management's view of a year-over-year improvement (~$64–$66 million improvement as stated).
Strong Cash Position and Debt Refinancing
Cash of $70.1 million at quarter end and debt refinanced/borrowings reduced to ~$147.1 million, described as roughly half of borrowings since the beginning of 2026; term loan maturities extended to 2032, improving liquidity and financial flexibility.
Cygnus Stable Profitability
Cygnus revenue grew 3% year-over-year (fifth consecutive quarter of growth) and generated $11.4 million of adjusted EBITDA with 68% adjusted EBITDA margin, supported by recurring HCP and ELISA product demand and expanding analytical services.
Commercial Execution and E-commerce Progress
Record quarterly e-commerce revenue and improved forecasting/order conversion; management cites materially improved commercial execution, predictive analytics and ordering automation leading to higher customer acquisition and repeat business.
Innovation & IP Wins
Product and platform launches (GMP-grade enzyme portfolio, upcoming GMP ModTail, new Cygnus Prism Mix-N-Go kit) and intellectual property expansion (new China CleanCap patent and prior European patents) strengthen competitive position and future GMP opportunity.
MX:MRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed